• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Longenesis, Medtronic study says quality of life improves with insulin pumps for T1D patients

July 13, 2022 By Sean Whooley

Longenesis medtronic
Image from Longenesis/Medtronic

Longenesis announced today that a study on type 1 diabetes care, in partnership with Medtronic (NYSE:MDT), supports insulin pump use.

Across less than three months, more than 85 patients participated in the research study aimed at providing qualitative and quantitative data on the quality of life for type 1 diabetics using insulin pumps compared to daily insulin injections.

Study sponsors used participant data to evaluate the efficiency of local reimbursement policies for insulin pumps and glucose monitors to help create more informed and patient-centric policies, according to a news release.

The data demonstrated that insulin pump use supports a higher quality of life, with cost representing the main reason to avoid or stop insulin pump usage, emphasizing the importance of patient-centric reimbursement policies for diabetes patients, Longenesis said.

Longenesis and Medtronic initially partnered last year to study diabetic patients’ quality of life, using Longenesis’ engagement tools to ensure dynamic patient identification, efficient digital onboarding and follow-up communication.

“Preparation and execution of type 1 diabetes research and advocacy project is Medtronic’s first cooperation with Longenesis,” a representative from the Medtronic Baltic office said in the release. “We highly value the professional attitude, friendly communication, and efficient and quick work of the team to prepare and execute the research project. The digital approach and tools used by Longenesis for this project have greatly impacted the speed of patient enrolment, are easy to use and comply with the highest standards of safety, data protection and patient-centric approaches.”

Approximately 80% of patients in the study reviewed their participation as satisfactory, with no patients expressing dissatisfaction, according to Longenesis. Results of the study are currently in pre-print for a number of journals and were presented as part of the European Congress of Endocrinology.

The project findings will serve as a tool for patient advocacy groups and respective stakeholders in drawing the government’s attention to the needs of type 1 diabetes patients in managing their care, both financially and personally, Longenesis said.

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: Longenesis, Medtronic

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS